{
    "id": 19931,
    "fullName": "PLK1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PLK1 positive indicates the presence of the PLK1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5347,
        "geneSymbol": "PLK1",
        "terms": [
            "PLK1",
            "PLK",
            "STPK13"
        ]
    },
    "variant": "positive",
    "createDate": "03/21/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5238,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute lymphocytic leukemia cells positive for PLK1 were sensitive to GW843682X, resulting in cell growth inhibition and cell cycle arrest in culture (PMID: 19421227).",
            "molecularProfile": {
                "id": 20367,
                "profileName": "PLK1 positive"
            },
            "therapy": {
                "id": 2805,
                "therapyName": "GW843682X",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4949,
                    "pubMedId": 19421227,
                    "title": "A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19421227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5239,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells positive for PLK1 were sensitive to GW843682X, resulting in cell growth inhibition and cell cycle arrest in culture (PMID: 19421227).",
            "molecularProfile": {
                "id": 20367,
                "profileName": "PLK1 positive"
            },
            "therapy": {
                "id": 2805,
                "therapyName": "GW843682X",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4949,
                    "pubMedId": 19421227,
                    "title": "A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19421227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5237,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TKM-080301 demonstrated safety and some efficacy in patients with advanced solid tumors, specifically, two patients (2/23) showed stable disease and a partial response (Cancer Res April 15, 2013 73; LB-289).",
            "molecularProfile": {
                "id": 20367,
                "profileName": "PLK1 positive"
            },
            "therapy": {
                "id": 3794,
                "therapyName": "TKM-080301",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4948,
                    "pubMedId": null,
                    "title": "Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-289"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5240,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Oncovin (vincristine) combined with GW843682X resulted in a synergistic effect in leukemia cells positive for PLK1, resulting in inhibition of cell growth and apoptotic induction (PMID: 19421227).",
            "molecularProfile": {
                "id": 20367,
                "profileName": "PLK1 positive"
            },
            "therapy": {
                "id": 3795,
                "therapyName": "GW843682X + Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4949,
                    "pubMedId": 19421227,
                    "title": "A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19421227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5245,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, advanced solid tumor cell lines positive for PLK1 were sensitive to SBE13 in culture, resulting in decreased cell proliferation and interruption of the mitotic cycle (PMID: 20139717).",
            "molecularProfile": {
                "id": 20367,
                "profileName": "PLK1 positive"
            },
            "therapy": {
                "id": 3796,
                "therapyName": "SBE13",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4953,
                    "pubMedId": 20139717,
                    "title": "Biological impact of freezing Plk1 in its inactive conformation in cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20139717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20367,
            "profileName": "PLK1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}